Product Details: Brand Athenese-Dx Model Name/Number ADX-410 Sample Capacity/Format 96 wells Volume Thermal Block Sample 0.2 mL Dimensions 355mm X 480mm X 485mm Power consumption 900VA The ALTA RT-96 is a Quantitative, real time PCR system which combined with easy to use software and optimized design features like highly sensitive optical system and uniform heating system provides precise and accurate results to your diagnostics and research demands.
RT PCR-Detection Kit
COVID-19 RT-PCR TEST - NO RNA PURIFICATION NEEDED! Results in less than 60 minutes, very easy-to-use. Made in USA, with clinical validations all over the world. FDA-EUA approved and CE cleared.
Our test kit has been approved and endorsed by Singapore's MOH (Ministry of Health) and HSA (Health Science Authority) since last year and we have been constantly supplying to the APAC countries during this period. (Japan, India, Singapore, Malaysia, Indonesia and etc.) * CE mark was attained in December 2020. * Our Tepat 1.0 SARS-CoV-2 RT-PCR provides for high-throughput, sensitive and specific detection of SARS-CoV-2 RNA extracted from nasopharyngeal swabs*. It can detect 6 copies of viral RNA per reaction with > 95% confidence. Clinical validation shows 100% sensitivity, with no cross-reaction with non-SARS-CoV-2 species. Key Highlights 1.5 hours from RNA to results Multiplex RdRp and M viral genes detection enhances sensitivity and specificity 100% coverage with 100% identity of all SARS-CoV-2 genomes in the world Detects 6 copies of viral RNA Whole process control: human RNase P
The COVID-19 RT-PCR Detection Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. 263a, to perform high complexity tests. Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper and lower respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infective status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial co-infection with other viruses. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The COVID-19 RT-PCR Detection Kit is intended for use by qualified trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The COVID-19 RT-PCR Detection Kit is only for use under the Food and Drug Administration's Emergency Use Authorization. PRINCIPLE OF DETECTION This product is a fluorescent probe-based Taqman RT-PCR assay system. Firstly, the RNA of SARS-CoV-2 will be reverse transcribed into cDNA by reverse transcriptase, and then PCR amplification will be performed with cDNA as template. During amplification of the template, the TaqMan probe will be degraded due to the 5'-3 polymerase activity and exonuclease activity of Taq DNA polymerase, then the separation of fluorescent reporter and quencher enables the fluorescent signal to be detected by instrument. The ORF1ab gene of SARS-CoV-2 will be detected qualitatively by FAM channel, the N gene of SARS-CoV-2 will be detected qualitatively by JOE channel, the E gene of SARS-CoV-2 will be detected qualitatively by ROX channel, and the internal reference will be detected by CY5 channel. dUTP and UNG enzyme are used in the kit to prevent contamination of the amplified products. Internal reference is used in the kit for quality control starting from sample collection
Indication: Qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider. Emergency use of this test is limited to authorized laboratories. Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. This letter is in response to your1 request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of your product,2 pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act. Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization. I. Criteria for Issuance of Authorization I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that: 1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus; 2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and, 3. There is no adequate, approved, and available alternative to the emergency use of your product. 4 II. Scope of Authorization I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.
Commodity: Covid-19 RT-PCR Detection Kit Spec.96 tests/kit Price:FOB SHANGHAI USD3.30/test, USD316.8/kit $3.60/TEST CIF NY AIRPORT OR OTHER MAJOR AIRPORTS USA OR EUROPE OR S. AMERICA OR MIDDLE EAST Payment: T/T ADVANCE 50% BALANCE BEFORE DEPARTURE OR Sight Irrevocable TRANSFERABLE LC Delivery: By AIR, 50days after receipt and confirmation of LC
Sample Types : Including Nasopharyngeal swab, Oropharyngeal swab, Sputum Controls : Internal control, UNG enzyme and dUTP used to reduce risk of contamination, false positive and false negative results Product Information Upper and lower respiratory specimens such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate. Authorized Laboratories Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. About Emergency Use Authorization (EUA) This test (1) has not been FDA cleared or approved, (2) has been authorized by FDA under an EUA for use by authorized laboratories, (3) has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and (4) is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The COVID-19 RT-PCRT est is a real-time reverse transcription polymerase chain reaction (rRT -PCR) test. The test can be run in a singleplex format (three individual assays) or multiplexed into a single reaction and amplification set up.
RTPCR testing kits are used for testing golden test processes to detect Covid19 viruses in patients.
Bitumen Primer * Bitumen Primer is Bituminous air curing ready mixed Acid & Alkali resistant special primer. Application * Concrete surface must be clean, dry and rough. No primer should be applied over smooth and wet surface. * After cleaning the concrete surface, one coat of Bitumen Primer should be applied with brush and allow to dry thoroughly. * The drying time will depend upon the temperature. * 24 Month at the temperature 30C (+2OC) Packing * Bitumen Primer: 25 Liter Drum Note * Bitumen Primer contains volatile and slightly toxic solvent. Keep away from spark and open flames at working area. * Bitumen premier it is manufactured using bitumen solution which is used for sealing of prime porous and non-porous surface, and also to protect residential and commercial building. * Bitumen Primer is used to protect substrate against corrosive attack, is suggested to apply anti-corrosive primer.It is best for protection against sub-striate against atmospheric corrosion and chemical corrosion. It is a mixed substance made up of organic liquids that are highly sticky, water proof, viscous,acid proof as with all surface coating, good Bitumen Premier is used for long life of the system. it is applied by brush or roller and allowed to dry before any water proofing treatment so to avoid solvent it is used in defects such as cracks, broken mortar joints, etc. are to be repaired prior to Bitumen primer application. Product Details: Grade Standard Technical Grade Physical State - Liquid Usage - Industrial Color - Black Characteristics: Appearance/Color - Pasty liquid/ black Chemical Base - Bituminous rubber emulsion. Density - 1.0 kg/l Curing Speed/ Rate - 3 - 4 hours Tack free after - 5 - 10 hours Cured after - 2 - 4 days (Dependent on ambient Solid Content by - temperature, substrate temperature, Weight - relative Water Content by weight - humidity and thickness of the coating) Bitumen Content - 41% by weight - Thixotropic (The viscosity can be adjusted by - Viscosity adding up to max. 5% of clean water. - Stir well prior use) - For light protection: 1.0 mm min. Coating - For greater protection: ~ 1.5 - 2.0 mm Thickness applied - in two coats. Water Penetration - 48 h, 1 bar: 78.5 cm2: 0 ml under Hydrostatic - 96 h, 4 bar: 78.5 cm2: 33 ml Pressure - Water vapor 6 x 10-7 mg / hmPa Permeability Service - -30 C to 200 C Temperature - Adhesion Concrete - Very good, Timber: Very good, Metal: Moderate Glass: Poor
ThermoFisher Scientific Accula System Rapid & Reliable RT-PCR Test for Corona in 30mins Product Details: Number of Reactions(Preps)/Kit : 25 Brand : Thermo Test Method : (SARS-CoV-2) RT-PCR Sample Type : Nasal Swab Test Time 30 min The Accula System from Thermo Fisher Scientific is a rapid diagnostic platform that combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Acculaâ?¢ SARS-CoV-2 Test has received an Emergency Use Authorization (EUA) from the FDA for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA) waived environments. Designed for use with the palm-sized Accula Dock, the Accula SARS-CoV-2 Test provides reliable, qualitative results in approximately 30 minutes
One-step real-time-PCR test for qualitative detection of genetic material of SARS-CoV-2 virus in upper and lower respiratory specimens collected from individuals suspected of COVID-19 infection. Targets the RdRp gene and E gene. Products with high specificity and sensitivity for accurate and reliable results.
!!!!!!!!!!Buy 40000 Test will free one machine !!!!!!!! Economical Practical Stable and accurate heating and temperature control system Excellent optical system Powerful comprehensive performance Capacity 96x 0.2ml tubes (low profile and standard) slides tube, 1x 96-well microplate Dynamic range 1~1010 Copies Applied probe 1st channel: FAM/ SYBR-Green 2nd channel: HEX, JOE, VIC, TET 3rd channel: ROX Texas -Red 4th channel: CY5 Test method four-fold fluorescence detection Thermal cycle temperature control semiconductor thermoelectric module Temperature Range 4.0�°C - 99.0�°C Heating and cooling Rate â?¥1.5�°C/sec Thermal Accuracy â?¤0.5�°C (at 90�°C) Thermal Uniformity â?¤0.5�°C (at 90�°C) Hot cover temperature range 50�°C - 108�°C Optical detection excitation wavelength 300-800nm Detection wavelength 500-800nm Fluorescence repeatability CVâ?¤ 3% Fluorescent linearity râ?¥0.99 coefficient of correlation Software application genotyping by qualitative, absolute quantitative, standard solution curve, relative quantitative and endpoint method Scanning method full plate, specified rank scanning Data export format Excel, CVS Custom report form support The operating system Window 7/8/8.1/10 Minimum computer configuration Intel or AMD Dual-2.8GHz, more than 4G memory and 128GB Power Supply AC 220V~, 50Hz,
Super long life refrigeration sheet modified by special process; Precision temperature control technology ensures that the temperature fluctuation of each hole is less than 0.1 ; Ultra high sensitivity PMT system combined with precision optical system ensures accuracy; New automatic hot cover technology can effectively prevent reagent evaporation; Maximum 6 channels fluorescence detection, no cross interference between channels; Intelligent operating system, flexible program setting, comprehensive analysis and report function;
This kit is intended for qualiativein vitro detection of Orf1ab and N genes of Novel Coronavirus 2019-nCoV which are found in throat swab,sputum and alveolar lavage fuid samples of suspected cases of pneumonia,suspected cases of clustering and other patients who need to carry out diagnosis or differential diagnosis of Novel Coronavirus 2019-nCoV infection.
Lowest detection line:200 copy/ml CE marks
25 tests per box
Cov-inu RT-PCR kit is a probe based Real Time PCR test designed for the qualitative de- tection of SARS-CoV-2 Coronavirus, the etiological agent of COVID-2019 and A + B Group Inuenza virus (orthomyxovirus). It is used to detect S- M2 ve NS1 genes in viral RNA. Description of the Kit Cov-inu RT PCR Kit is a multiplex PCR kit that is used for the simultaneous detection of COVID-19 agent SARS-COV-2 and Inuenza A and Inuenza B viruses from the same sample. Coronaviruses are a large family of viruses that cause infections in humans and other mammals (such as camels, cats, dogs, and bats). The SARS-CoV-2 virus is a new coronavirus that was identified by the World Health Organization (WHO) (1) on February 11, 2020. Inuenza is caused by three types of immunological RNA viruses (A, B and C) in the Orthomyxoviridae family. Seasonal inuenza is typically caused by three main hem- agglutinin subtypes (H1, H2, and H3) and two neuraminidase subtypes (N1 and N2). It is important that public health laboratories around the world conduct detailed surveillance to monitor the spread and impact of the pandemic H1N1 2009 virus, as well as predict future changes in virulence (4). Therefore, methods for rapid diagnosis, case detection and follow-up of this new pathogen in the human population are necessary to develop appropriate management strategies to reduce morbidity and mortality. The test works with single-stage real time reverse transcriptase polymerase chain reaction (On- eStep RT-PCR) with serum, lower respiratory tract samples (e.g. bronchoalveolar lavage, sputum, tracheal aspirate), and upper respiratory tract samples (e.g. nasopharyngeal uids, nasal swab) from individuals who demonstrate clinical criteria set for COVID-19 by WHO (2) and CDC (Center for Disease Control and Prevention) (3). This kit is an In-vitro diagnostic kit using specific primers designed for qualitative detection of genomic RNAs of SARS-CoV-2, Inuenza A and Inuenza B virus.